Book a Meeting

IgA Antibody Drug Ejects Problematic Proteins from Cancer Cells

More Info

Antibody-based therapies have marked a significant advancement in cancer treatment, offering targeted approaches to combat malignancies. Traditionally, these therapies have focused on extracellular proteins associated with cancer cells, leaving intracellular oncoproteins, which play a pivotal role in cancer progression, largely unaddressed. This article explores a groundbreaking study that unveils a novel therapeutic strategy using IgA antibodies capable of infiltrating cancer cells to extricate and eliminate problematic proteins from within, heralding a new frontier in oncological research and treatment.

IgA Antibodies: Beyond Surface-Level Intervention

IgA, an antibody subtype primarily known for its role in mucosal immunity, has emerged as a key player in the fight against cancer. Unlike most antibodies that cannot penetrate cell membranes, IgA antibodies exhibit a unique ability to enter cancer cells and target intracellular oncoproteins. This capability is not only a significant departure from conventional antibody therapy but also a strategic attack against the elusive oncoproteins residing deep within cancer cells, including the notoriously difficult to target KRAS proteins.

Targeting KRAS Mutations: A Breakthrough in Cancer Therapy

KRAS mutations are implicated in over 30% of cancers, representing a critical target for therapeutic intervention. However, until recently, the intracellular location of KRAS proteins rendered them virtually untouchable by traditional chemotherapy. The innovative application of IgA antibodies to target KRAS mutations offers a promising solution to this longstanding challenge. Experiments have demonstrated that IgA antibodies, specifically designed to target the KRASG12D mutation—one of the most common oncogenic mutations—can significantly slow tumor growth in mice without evident side effects, outperforming experimental KRASG12D inhibitors.

Fig. 1: KRASG12D-specific dIgA1 captures mutant KRAS during trafficking. (Biswas, et al., 2023)Fig 1. KRASG12D-specific dIgA1 captures mutant KRAS during trafficking.1

Harnessing IgA's Natural Pathway

The body's natural mechanism for IgA transport across epithelial cells to mucosal layers, via the Polymeric Immunoglobulin Receptor (PIGR), serves as the foundation for this therapeutic strategy. By leveraging this pathway, IgA antibodies are engineered to carry out a similar function within cancer cells—binding to abnormal proteins and extracting them from the cell. This process not only disrupts the cancer cell's internal machinery but also marks the cell for destruction by the immune system.

Enhancing Immune System Engagement

Further research has revealed that IgA antibodies can make cancer cells more susceptible to attack by T cells, the body's natural cancer fighters. This dual action, where IgA antibodies directly target cancer cells while also flagging them for T cell recognition, could potentially enhance the efficacy of other immunotherapies, such as immune checkpoint inhibitors. The synergy between IgA-based therapies and existing immunotherapeutic approaches could pave the way for more comprehensive and effective cancer treatment regimens.

Expanding the Reach of IgA Antibodies

The versatility of IgA antibodies extends beyond targeting surface-proximal oncoproteins. Scientists are exploring the potential of IgA antibodies to reach deeper into the cellular interior, targeting cytoplasmic and even nuclear proteins. This endeavor involves designing antibodies against various oncoproteins, such as the IDH1 mutation associated with certain brain, colon, and lung cancers. Preliminary findings suggest that enhancing PIGR expression in tumors could amplify the therapeutic impact of IgA antibodies, underscoring the adaptability and potential breadth of this approach.

Broadening the Horizon for Cancer Therapy

The investigation into IgA antibodies' capacity to traverse the cellular landscape of different cancer types indicates a wide applicability across epithelial-derived tumors. High levels of PIGR expression in renal, endometrial, and endometrial carcinoma samples suggest that IgA's mechanism of action could be a common feature in epithelial tumors. This discovery opens the door to a new realm of therapeutic possibilities, where IgA antibodies could be engineered to carry diverse payloads directly into cancer cells, offering a multifaceted approach to cancer treatment.

Challenges and Future Directions

While the promise of IgA antibody therapy is evident, numerous questions remain regarding the intricacies of its mechanism, including how these antibodies interact with target proteins inside cancer cells and the fate of the IgA-protein complexes post-extraction. Addressing these questions will be crucial for optimizing the efficacy and safety of IgA-based therapies. Moreover, efforts to deepen the penetration of IgA antibodies into cellular compartments, including the nucleus, are underway, with the potential to target transcription factors that drive cancer progression.


The development of IgA antibody drugs represents a paradigm shift in cancer therapy, offering a novel method to target and eliminate oncogenic proteins from within cancer cells. By exploiting the unique properties of IgA antibodies to infiltrate cancer cells and disrupt their internal oncoproteins, this approach opens new avenues for treating a wide range of cancers. Coupled with their potential to synergize with existing immunotherapies, IgA antibody drugs not only embody a significant scientific breakthrough but also offer hope for more effective and comprehensive cancer treatments in the future.

In the realm of Creative Biolabs, we transcend the ordinary team dynamic. We emerge as an agile and seasoned force, wholly committed to delivering a wide range of solutions in non-IgG antibody development on a global scale. Yet, our offerings extend beyond mere fulfillment of your distinctive demands; they center on grasping and translating them with precision. This is made possible through an extensive selection of IgA antibodies sourced from various species, including humans, rats, mice, and bovines, all meticulously crafted to cater to a multitude of objectives. We warmly welcome you to engage with us for further insights that align seamlessly with your specific needs.

Recommended Services

Services Features Price
Therapeutic IgA Antibody Discovery We have experienced experts and advanced platforms that can provide excellent discovery services on therapeutic IgA antibodies. Inquiry
Chimeric IgA Antibody Engineering Tremendous efforts have been devoted at Creative Biolabs to further optimize the applied medium formulation and develop more advanced process strategies to boost IgA titers and increase the process output to yield the desired amounts. Inquiry
IgA Production and Purification Our seasoned scientists can customize the most suitable IgA products and services according to the specific requirements of customers. Inquiry
IgA Glycosylation Service We can help worldwide customers to evaluate predominant glycan structures by N-glycosylation profile analysis of these recombinant IgA antibodies. Inquiry


  1. Biswas, Subir, et al. "Targeting intracellular oncoproteins with dimeric IgA promotes expulsion from the cytoplasm and immune-mediated control of epithelial cancers." Immunity 56.11 (2023): 2570-2583.

!! For Research Use Only. Our products and services are NOT intended for diagnostic or therapeutic applications.

Online Inquiry
For Research Use Only. Our products and services are NOT intended for diagnostic or therapeutic applications.






Stay Up To Date

© 2024 Creative Biolabs All Rights Reserved